Trial · NCT02549573
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Activities-specific Balance Confidence (ABC) Scale | Baseline and after week 6 | Scale from 0 to 100% where an increase in percent represents an improvement in balance confidence. |
| Secondary | Change From Baseline in Movement Disorder Societies Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (Motor Examination) | Baseline and after week 6 | MDS-UPDRS Part III is a sub-scale of MDS-UPDRS. Sub-scale scores range from 0 (best score possible) to 72 (worst score possible). A negative change from baseline represents an improvement in motor function. |
| Secondary | Change From Baseline in Modified Physical Performance Test (M-PPT) | Baseline and after week 6 | Investigator scale assessing 9 domains of physical functioning where total scores range from 0 to 28 with higher scores indicating better physical performance. A positive change from baseline represents an improvement in physical performance. |
| Secondary | Change From Baseline in Timed-Up-and-Go (TUG) Test | Baseline and after week 6 | Test captures the amount of time for a subject to get up from an arm chair, walk 3 meters, turn around, walk back to chair, and sit. A negative change from baseline represents an improvement of physical function. |
| Secondary | Change From Baseline in 6-Minute Walk Test (6MWT) | Baseline and after week 6 | Objective performance based measure of functional exercise capacity that measures the distance a subject can cover on a 30 meter flat walking area over 6 minutes. A positive change from baseline represents an improvement in the distance walked (ft) in 6 minutes. |
| Secondary | Change From Baseline in Montreal Cognitive Assessment (MoCA) | Baseline and after week 6 | The MoCA is a validated, 30-point test (sum of the 6 domains), with scores ranging from 0 (worst) to 30 (best). The test is designed to assess several cognitive domains, including visuospatial abilities (5 points), animal naming (3 points), attention (6 points), language (3 points), abstraction (2 points), delayed recall (5 points), and orientation to time and place (6 points). Total MoCA scores higher than 26 indicate normal cognitive function. A positive change from baseline represents an improvement in cognitive function. |
| Secondary | Change From Baseline in MDS-UPDRS Part I A | Baseline and after week 6 | MDS-UPDRS Part I A is a sub-scale of MDS-UPDRS. Sub-scale scores range from 0 (best score possible) to 24 (worst score possible). A negative change from baseline represents an improvement in non-motor experiences of daily living (investigator rated). |
| Secondary | Number of Participants in Each Category of Clinical Global Impression of Change (CGI-C) | After week 6 | Investigator's impression of change in the subject's symptoms from baseline assessment visit to end of study assessment, on a 7-point scale ranging from very much improved to very much worse. |
| Secondary | Change From Baseline in MDS-UPDRS Part II | Baseline and after week 6 | MDS-UPDRS Part II is a sub-scale of MDS-UPDRS. Sub-scale scores range from 0 (best score possible) to 52 (worst score possible). A negative change from baseline represents an improvement in motor experience of daily living. |
| Secondary | Change From Baseline in MDS-UPDRS Part IV | Baseline and after week 6 | MDS-UPDRS Part IV is a sub-scale of MDS-UPDRS. Sub-scale scores range from 0 (best score possible) to 24 (worst score possible). A negative change from baseline represents fewer motor complications. |
| Secondary | Change From Baseline in MDS-UPDRS Part I B | Baseline and after week 6 | MDS-UPDRS Part I B is a sub-scale of MDS-UPDRS. Sub-scale scores range from 0 (best score possible) to 28 (worst score possible). A negative change from baseline represents an improvement in non-motor experiences of daily living (subject rated). |
| Secondary | Change From Baseline in Clinical Global Impression of Severity (CGI-S) | Baseline and after week 6 | Investigator's impression of the severity of the subject's illness on a 7-point scale ranging from normal (1) to among the most extremely ill subjects (7). A negative change from baseline represents a decrease in the severity of the subject's illness. |
| Other | Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) | Baseline and after week 6 | PDQ-39 is a scale measuring subject reported aspects of functioning and well-being. Each of the 39 items is rated using a 5-points Likert scale, with 0 for never having difficulties/problems and 4 for all always having difficulties/problems. The total score is the sum of the 39 items, with a minimum score of 0 and a maximum score of 156. A negative change from baseline represents an improvement in functioning and well-being. |
| Other | Change From Baseline in Parkinson's Fatigue Scale (PFS-16) | Baseline and after week 6 | PFS-16 is a subject-reported scale evaluating the physical effects of fatigue and its impact on daily function, with a minimum score of 16 and a maximum score of 80. Ratings are based on feelings and experiences over the prior 2 weeks, with scoring ranging from 1 (strongly disagree) to 5 (strongly agree), where lower scores are associated with less fatigue and higher scores are associated with greater fatigue. A negative change from baseline represents an improvement in the physical effects of fatigue and the impact on daily function. . |
| Other | Hospital Anxiety and Depression Scale - Change From Baseline in Anxiety | Baseline and after week 6 | The Hospital Anxiety and Depression Scale is a 14-item Investigator-rated scale designed to determine levels of anxiety and depression in people with physical health problems. Seven items relate to anxiety and 7 items related to depression, where the scale ranges from 0 (best score possible) to 21 (worst score possible). A negative change from baseline represents a decrease in anxiety. |
| Other | Number of Participants in Each Category of Patient Global Impression of Change (PGI-C) | After week 6 | Self reported (caregiver, if applicable) impression of change in the subject's symptoms from baseline assessment visit to end of study assessment, on a 7-point scale ranging from much improved to very much worse. |
| Other | Change From Baseline in Number of Falls as Reported by the Subject in the Past 1 Week | Baseline and after week 6 | Subject reported number of falls. A negative change from baseline represents a decrease in the frequency of falls. |
| Other | Change From Baseline in Patient Global Impression of Severity (PGI-S) | Baseline and after week 6 | Self reported (caregiver, if applicable) impression of the severity of the subject's illness on a 7-point scale ranging from normal (1) to among the most extremely ill subjects (7). A negative change from baseline represents a decrease in the severity of the subject's illness. |
| Other | Hospital Anxiety and Depression Scale - Change From Baseline in Depression | Baseline and after week 6 | The Hospital Anxiety and Depression Scale is a 14-item Investigator-rated scale designed to determine levels of anxiety and depression in people with physical health problems. Seven items relate to anxiety and 7 items related to depression, where the scale ranges from 0 (best score possible) to 21 (worst score possible). A negative change from baseline represents a decrease in depression. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02549573/registered